Table 2.
Baseline characteristics and association with time to first relapse
| Characteristic | HR (95% CI) | P-value |
|---|---|---|
| General characteristics | ||
| Age, years | 0.99 (0.98, 1.01) | 0.50 |
| Female | 1.37 (0.99, 1.91) | 0.057 |
| Symptom duration, months | 1.00 (0.98, 1.01) | 0.81 |
| Cardiovascular risk factors | ||
| Hypertension | 1.30 (0.99, 1.71) | 0.056 |
| Diabetes | 1.49 (0.97, 2.31) | 0.07 |
| History of venous thrombosis | 2.27 (1.12, 4.62) | 0.024 |
| Clinical symptoms | ||
| Headache | 1.30 (0.97, 1.73) | 0.08 |
| Jaw claudication | 1.09 (0.83, 1.42) | 0.54 |
| PMR | 0.88 (0.67, 1.15) | 0.35 |
| Vision loss transient | 0.97 (0.57, 1.64) | 0.90 |
| Vision loss permanent | 0.77 (0.41, 1.45) | 0.42 |
| Leg claudication | 2.53 (1.03, 6.20) | 0.043 |
| Systemic manifestations | ||
| Weight loss >2 kg | 1.10 (0.82, 1.46) | 0.54 |
| Fatigue | 0.84 (0.64, 1.11) | 0.23 |
| Initial treatment | ||
| Prednisone dose, mg | 1.00 (0.99, 1.01) | 0.53 |
| Prednisone >40 mg vs ≤40 mg | 1.18 (0.88, 1.57) | 0.27 |
| Aspirin | 1.07 (0.82, 1.40) | 0.63 |